在心力衰竭的治疗中使用Empagliflozin
Aimen Shafiq1, Ishaque Hameed1, Jan Biegus2
1Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Future cardiology
|June 12, 2024
概括
恩帕格利弗洛辛通过减少住院和死亡率,改善患者的生活质量,有效治疗心力衰竭 (HF). 这种药物对同时存在的慢性病有好处,并增强了其他HF疗法的使用.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學.
背景情况:
- 心力衰竭 (HF) 影响全球超过6000万人,代表着重大的公共卫生挑战.
- 最初批准用于2型糖尿病的empagliflozin在治疗慢性HF方面表现有前途.
研究的目的:
- 审查empagliflozin在心力衰竭患者中的药理动力学,药理动力学,安全性和疗效.
- 探索Empagliflozin在各种高压子组和临床环境中的好处.
主要方法:
- 对临床试验数据的分析证明了empagliflozin对HF结局的影响.
- 对empagliflozin的药理动力学和药理动力学概况的审查.
主要成果:
- 恩帕格利弗洛辛显著降低了HF住院和死亡的复合终点.
- 无论左心室喷射分数如何,人们都观察到生活质量的改善.
- 恩帕格利弗洛辛通过减轻高血症风险来促进其他HF药物的使用,并有利于同时存在慢性脏疾病的患者.
结论:
- 恩帕格利弗洛辛是心力衰竭的宝贵治疗选择,具有广泛的益处.
- 其有利的特征,包括每天服用一次,药物相互作用最小,缺乏定位,增强了患者的坚持和管理.
- 恩帕格利弗洛辛的积极影响延伸到并发性慢性病患者,进一步巩固其在综合性HF护理中的作用.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
421
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421
01:22Heart Failure Drugs: Diuretics
363
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
363
01:22Heart Failure Drugs: β-Blockers
336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
01:23Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
01:26Heart Failure Drugs: Inotropic Agents
570
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
570
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
189
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
189